Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade

Sarepta Therapeutics’ CEO Doug Ingram said Wednesday he would retire after a tumultuous decade in which he turned the biotech into a $15 billion company by pushing three different treatments for Duchenne muscular dystrophy to approval and then watched that value collapse amid investigations into the safety of its gene therapy and the emergence of superior versions of its other products.  

The company is currently searching for a successor. Ingram will retire by the end of the year, if a new CEO is not found before then.

On an earnings call, Ingram said he was leaving because his wife and son were recently diagnosed with myotonic dystrophy, a form of muscular dystrophy that Sarepta started working on in 2024 through a new partnership.  

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In